IRADIMED CORP
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $83.8M | $73.2M | $65.6M | $53.3M | $41.8M |
| Cost of revenue | $19.5M | $16.9M | $15.4M | $12.0M | $9.8M |
| Gross profit | $64.3M | $56.4M | $50.2M | $41.3M | $32.0M |
| Research and development | $3.0M | $2.8M | $2.9M | $2.3M | $1.9M |
| Operating expenses | $38.2M | $34.4M | $30.1M | $25.7M | $22.2M |
| Operating income | $26.1M | $22.0M | $20.0M | $15.6M | $9.8M |
| Pretax income | $28.4M | $24.3M | $21.7M | $16.2M | $9.8M |
| Income tax expense | $5.9M | $5.0M | $4.5M | $3.4M | $510,816 |
| Net income | $22.5M | $19.2M | $17.2M | $12.8M | $9.3M |
| Balance Sheet | |||||
| Cash and equivalents | $51.2M | $52.2M | $49.8M | $58.0M | $62.0M |
| Current assets | $81.2M | $75.2M | $76.0M | $77.5M | $76.2M |
| Total assets | $108.8M | $98.3M | $92.2M | $85.5M | $82.9M |
| Current liabilities | $10.2M | $8.5M | $16.3M | $8.6M | $6.8M |
| Total liabilities | $14.2M | $11.5M | $20.7M | $11.8M | $10.7M |
| Stockholders' equity | $94.6M | $86.8M | $71.4M | $73.7M | $72.2M |
| Cash Flow Statement | |||||
| Cash from operations | $24.9M | $25.6M | $13.5M | $10.0M | $11.3M |
| Depreciation and amortization | $1.2M | $818,000 | $765,180 | $670,673 | $1.4M |
| Stock-based compensation | $2.9M | $2.5M | $2.2M | $1.4M | $1.5M |
| Capital expenditure | $7.8M | $8.0M | $7.4M | $823,019 | $482,325 |
| Free cash flow | $17.2M | $17.6M | $6.0M | $9.2M | $10.8M |
| Dividends paid | $15.0M | $13.7M | $13.2M | $12.6M | — |
Shares outstanding 12.8M · Free float 30.0%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.